TDT
-
News
JUST RELEASED | 5th Edition of TIF’s Guidelines for the Management of Transfusion Dependent β-Thalassaemia
This edition stands as a seminal resource that provides critical guidance and recommendations to healthcare professionals across various specialties, researchers and all stakeholders involved in the care of individuals affected…
Read More » -
News
BREAKING | Vertex and CRISPR’s Gene-editing Therapy Casgevy Receives Early FDA Approval for β-Thalassaemia Treatment
Just one month prior, Casgevy made history as the first CRISPR gene editing therapy to enter the US market when it was approved for sickle cell disease. Now, the FDA…
Read More » -
News
NEW PUBLICATION | Short Guide For the Management of TDT (2nd Edition)
The 4th edition of the original full-length Guidelines, published in June 2022, includes a full review of the evidence supporting almost each recommendation for physicians to know all the facts…
Read More » -
News
It’s Here: The 4th Edition Of TIF Guidelines For The Management of TDT
TIF, its Board of Directors, and its International Scientific Advisory Board proudly present the 4th Edition of the Federation’s most prestigious and renowned publication, the TIF Guidelines For The Management…
Read More » -
News
TIF’s Statement on Accessibility of Gene Therapy for Thalassaemia
The Thalassaemia International Federation (TIF) expresses its disappointment about the outcome of the reimbursement negotiation process concerning gene therapy (Zynteglo™) for transfusion-dependent thalassaemia patients, announced last week. The Federation’s distress…
Read More » -
News
Blood Donors’ COVID-19 Antibodies: Do They Have A Positive Significance for Blood Recipients?
According to recent data released by the American Red Cross, in the first week of March 2021 more than 20% of blood donations from unvaccinated people in the US had…
Read More »